These results were also validated in an additional cohort of patients with MCC treated with checkpoint inhibitors51 (method details; Figure S21), showing higher fraction of clones with max activity of the FGFBP2-NKG7 program in non-responders (p = 0.098; Figure 5G). This evidence concerns the gene NKG7 and Merkel cell skin cancer.